乐伐替尼用于进展期肝癌治疗的研究现状  

Status quo of lenvatinib in the treatment for advanced hepatocellular carcinoma

作　　者：贺国盛[1] 谢生智[1] 朱曦龄[1] 黎功[1] 

机构地区：[1]武警总医院肿瘤二科,北京100039

出　　处：《武警后勤学院学报（医学版）》2017年第2期181-184,共4页Journal of Logistics University of PAP（Medical Sciences）

摘　　要：乐伐替尼是一个多靶点酪氨酸激酶抑制剂,同时具有强大的抗血管生成作用,最近被食品和药物管理局(food and drug administration,FDA)批准用于治疗难治性分化型甲状腺癌及与依维莫司联合用于进展期肾癌。在应用于肝癌的I/II期临床试验中,乐伐替尼也显示出了非常好的治疗效果,对比索拉非尼的III期临床试验结果近期也即将公布,实验结果将决定乐伐替尼是否可以作为肝癌的突破性药物。Lenvatinib is a multitargeted tyrosine-kinase inhibitor with potent antiangiogenic effects, and has recently been approved for treating refractory differentiated thyroid carcinoma by Food and Drug Adminstration （FI）A）. It has been also approved in the treatment for advanced renal cell carcinoma combined with everolimus. Lenvatinib has shown highly promising therapeutic efficacy on advanced hepatocellular carcinoma in the Phase I/II clinical trial. Its results of Phase III clinical trial contrasted with sorafenib will be publicized in the near future, which will determine whelher lenvatinib represents a breakthrough drug in the treatment for hepatocellular carcinoma.

关 键 词：肝细胞癌 分子靶向药物 乐伐替尼 

分 类 号：R735.7[医药卫生—肿瘤]